Merck (MRK) Shares See Pressure on Vorapaxar Study Adjustments

Merck & Co. Inc. (NYSE: MRK) shares are trading lower following adjustments to the clinical studies for vorapaxar. The stock is down 5.8% this morning.

The following two changes are being implemented in two studies:

• In the TRACER study, patients will discontinue study drug and investigators are to begin now to close out the study in a timely and orderly fashion.
  
  
• In the TRA-2P study, study drug will be continued in patients who had experienced a previous heart attack or peripheral arterial disease (approximately 75 percent of the patients enrolled in the study), and will be immediately discontinued in patients who experienced a stroke prior to entry into the study or during the course of the study.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Molina Healthcare to join S&P MidCap 400, Construction Partners to join S&P SmallCap 600
• Standard Nuclear indicating to open at $15-$16, IPO priced at $15
• Merck's Keytruda meets PFS endpoint in endometrial cancer trial